Ambrose Healthcare and the Precision Health Technologies Accelerator Enter a Long Term Collaboration to develop New Treatments for Rare Diseases

Cambridge & Birmingham, United Kingdom (UK); 28 February 2023.

Ambrose Healthcare Ltd (Ambrose Healthcare), announces today a long-term collaboration with the Precision Health Technologies Accelerator (PHTA), to support its development of new treatments for #rarediseases #raredisease #rarediseaseday.

The U.S. NIH recognises some 7,000 rare diseases[1], affecting around 400 million people globally[2], for which approximately 600 therapies have been approved to date by the U.S. Food and Drug Administration[3]. As such there is still much to be done to close this gap.

Ambrose Healthcare is a specialist pharmaceutical company established to develop and provide treatments for rare diseases and the unmet medical needs of patients managed in a hospital or specialist care setting.

The PHTA, situated on Birmingham Health Innovation Campus at the heart of the Birmingham Health Partners life sciences ecosystem, will contribute and provide access to expertise, resources and infrastructure to enable translation of medical innovations developed through this collaboration.

The two organisations will be working together to bring new solutions for improving the lives of rare disease patients, globally.

Commenting, Professor Gino Martini, CEO of the PHTA said, "This is a wonderful example of how the bringing together of experienced specialists, including companies, physicians, innovators, patients and healthcare providers can lead to and accelerate new treatments for addressing important unmet medical needs. I am delighted that the PHTA has established this collaboration with such an experienced group as Ambrose Healthcare, and a new integrated way of innovating for the benefit of patients.”

Toby Wilson Waterworth, Founder and Chief Executive of Ambrose Healthcare commented, “I am pleased to be involved with such a progressive thinking group and to be extending Ambrose Healthcare’s collaborative network to include the the PHTA, and opening the door to the expertise of the University of Birmingham and its National Health Service partners.”

For more information please contact:

Ambrose Healthcare

Toby Wilson Waterworth, CEO

Adam Michael, Director of Communications

[email protected]

+44 7775 881 813

Precision Health Technologies Accelerator

Professor Gino Martini, CEO

[email protected]

+44 7543 551 900

Louise Stanley, Communications Manager

[email protected]

About Precision Health Technologies Accelerator

The Precision Health Technologies Accelerator (PHTA) is the University of Birmingham’s signature health and life sciences research facility, providing approximately 70,000 sq ft of state-of-the-art laboratory, incubation and collaboration space and was supported with funding from GBSLEP.

PHTA will soon occupy the top three floors of No.1 BHIC – the flagship building of the ambitious Birmingham Health Innovation Campus which is being delivered in partnership with experienced investor-developers Bruntwood SciTech.

Working closely alongside Birmingham Health Partners, PHTA offers access to a wide range of expertise in clinical research, trials and health data, as well as opportunities to work with key opinion leaders across the academic and clinical spectrum. Its physical facilities will include wet and dry lab space; prototype development and small-batch manufacturing; business incubation space and flexible hot-desking.

About Ambrose Healthcare (www.ambrosehc.com)

Ambrose Healthcare Ltd is a specialist pharmaceutical company, with ambitious plans to address ‘market pull’ – the call from patient groups and the medical community – to provide treatments for rare diseases and the unmet medical needs of patients managed in a hospital or specialist care setting.

Whilst the NIH lists more than 10,000 rare diseases[1], FDA reports only 600 drug approvals to date in 2020[3]. Some 400 million people worldwide are affected by rare diseases[2].

The company is led by industry experienced founder Toby Wilson Waterworth and a Leadership Team with a proven track record, along with deep international roots in the pharmaceutical industry.

The Ambrose Healthcare team is seeking to replicate the success of its previous venture, where, applying the same rare disease, hospital focused strategy, and receiving $50M of investment in equity and grants, it delivered a product portfolio valued at $500M (Top 4 Global Accountancy Firm).

Ambrose Healthcare, through acquisition, licencing and collaboration, is developing a portfolio of commercial and clinical stage therapeutic assets.

The company will commercialise its products in its core markets of the US, Europe, and the Middle East, and in other territories via licencing or distribution agreements with established pharmaceutical companies.

References:

1. U.S. National Institutes of Health (rarediseases.info.nih.gov/about)

2. CamRARE – Cambridge Rare Disease Network (www.camraredisease.org/)

3. National Organization for Rare Disorders (rarediseases.org/new-study-investigates-the-number-of-available-orphan-products-generics-and-biosimilars/

Forward Looking Statements

While Ambrose Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Ambrose Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Ambrose Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.